Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis

• Main Authors: Shuai Tang (Author), Yichen Duan (Author), Tao Yuan (Author), Yuting Hu (Author), Liang Yuan (Author), Ning Shen (Author), Yixian Fu (Author), Congying Pu (Author), Xiaomin Wang (Author), Jun Xu (Author), Xiaojing Lan (Author), Ying Zheng (Author), Yu Zhou (Author), Hong Zhu (Author), Jian Ding (Author), Meiyu Geng (Author), Min Huang (Author)
• Format: Book
• Published: Elsevier, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies lacking effective therapies. KRAS mutations that occur in over 90% of PDAC are major oncogenic drivers of PDAC. The MAPK signaling pathway plays a central role in KRAS-driven oncogenic signaling. However, p...